WO2014199131A1 - Fixed Dose Pharmaceutical Composition - Google Patents

Fixed Dose Pharmaceutical Composition Download PDF

Info

Publication number
WO2014199131A1
WO2014199131A1 PCT/GB2014/051772 GB2014051772W WO2014199131A1 WO 2014199131 A1 WO2014199131 A1 WO 2014199131A1 GB 2014051772 W GB2014051772 W GB 2014051772W WO 2014199131 A1 WO2014199131 A1 WO 2014199131A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
fixed dose
dose pharmaceutical
composition according
pharmaceutically acceptable
Prior art date
Application number
PCT/GB2014/051772
Other languages
English (en)
French (fr)
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Original Assignee
Cipla Limited
Turner, Craig Robert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, Turner, Craig Robert filed Critical Cipla Limited
Publication of WO2014199131A1 publication Critical patent/WO2014199131A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • the present invention relates to a fixed dose pharmaceutical composition comprising at least two anti-glaucoma agents, a process for preparing such a fixed dose pharmaceutical composition and the use of the said fixed dose pharmaceutical composition for the treatment of glaucoma.
  • Glaucoma is an ocular disorder characterized by elevated intraocular pressure, excavation of the optic nerve head and gradual loss of the vision field.
  • An abnormally high intraocular pressure will have a generally detrimental effect on the eye; and there are clear indications that this is probably the main factor causing degenerative changes of the retina in glaucoma patients.
  • open-angle glaucoma the pathophysiological mechanism underlying open-angle glaucoma is still unknown. If not treated successfully the disease will usually proceed to blindness sooner or later, its course towards that stage being characterized by a slow but progressive loss of vision.
  • the IOP will normally be within the range of from 12 to 22 mm Hg. At higher values, e.g. exceeding 22 mm Hg, there is a risk that the eye may be affected.
  • the so-called low-tension glaucoma lesions will occur at intraocular pressure levels which are generally regarded as physiological. Possibly this may be due to an increased pressure sensitivity of the eye of such an individual.
  • the opposite type of phenomenon is known, i.e. some individuals may have in abnormally high intraocular pressure without any noticeable distinct defects in their vision field or optic nerve head. Such conditions are usually named "ocular hypertension".
  • Glaucoma treatments may be given by means of drugs, laser or surgery.
  • the purpose is to lower the IOP or alternatively, the purpose may be to increase the flow of the aqueous humor which too will be a means of lowering the pressure.
  • the prostaglandin analogues are a group of compounds that have become the most frequently used ocular hypotensive drugs owing to their efficiency in reducing intraocular pressure and the low incidence rate and severity of adverse events, in particular in the absence of systemic side effects, especially in comparison to the beta-blockers.
  • Prostaglandins are ubiquitous local hormones that produce ocular inflammation and hypertension in high levels but in smaller amounts reduces IOP.
  • Prostaglandins are potent ocular hypotensives as first line therapy for ocular hypertension and Primary Open-Angle Glaucoma (POAG) and such prostaglandins include latanoprost, travoprost, tafluprost, unoprostone and bimatoprost.
  • POAG Primary Open-Angle Glaucoma
  • Tafluprost (1-methylethyl (5Z)-7-[(lR,2R,3R,5S)-2-[(lE)-3,3-difluoro-4-phenoxy-l-butenyl]- 3,5-dihydroxycyclopentyl]-5- heptenoate)24,31 is a 16-phenoxy analog of PGF2a, with a 15,15- difluoro substitution.21 It is presently available in two formulations, ie, with benzalkonium chloride (BAK)- Tapros® in Japan (Santen Pharmaceutical Co. Ltd., Osaka, Japan) and preservative-free in Europe, ie, Taflotan® (Santen Oy, Finland), both in 0.0015% (15 ⁇ g/mL) concentrations.
  • BAK benzalkonium chloride
  • CAI Systemic carbonic anhydrase inhibitors
  • Such topical carbonic anhydrase inhibitors include dorzolamide and brinzolamide.
  • Dorzolamide is the first topical carbonic anhydrase inhibitor with substantial ocular hypotensive efficacy to be made available for clinical use.
  • Dorzolamide has been found to be well tolerated and to reduce intraocular pressure (IOP) by 14% to 24% in adults.
  • Brinzolamide is described chemically as: (R)-(+)-4- Ethylamino-2-(3-methoxypropyl)-3,4- dihydro-2H-thieno [3,2-e]-l,2-thiazine-6-sulfonamide-l,l- dioxide.
  • Acetazolamide is chemically described as N-(5-Sulfamoyl-l ,3,4-thiadiazol-2-yl)acetamide and has the following chemical structure
  • Methazolamide is chemically described as N-[5-(aminosulfonyl)-3-methyl-l,3,4-thiadiazol- 2(3H)-ylidene]acetamide
  • prostaglandin derivatives act by lowering intraocular pressure by increasing uveoscleral outflow (the minor pathway for the removal of aqueous humour from the anterior chamber of the eye) and decreasing episcleral venous pressure and carbonic anhydrase inhibitors act by decreasing production of aqueous humour.
  • Glaucoma is a condition in which the trabecular meshwork which aids in the drainage of the aqueous fluid is affected or damaged thereby inhibiting or preventing the drainage of the aqueous fluid and building up intraocular pressure (IOP) further damaging the optic nerve thus impairing the vision.
  • IOP intraocular pressure
  • the combination of prostaglandin derivatives and carbonic anhydrase inhibitors may provide a complimentary mechanism of action as both are efficacious in reducing the IOP.
  • Prostaglandin derivatives acts by increasing the uveoscleral outflow of aqueous humor and carbonic anhydrase inhibitors act by reducing the aqueous humor production.
  • the different mechanisms of action will lead to an additive effect in reducing the intraocular pressure.
  • the inventors of the present invention have further appreciated that, in the case of ocular medications administered in the form of eye drops the droplet size, number of doses administered per day and wastage of medicament during instillation are also important factors to consider. Furthermore, it has been appreciated that patients may tend to skip doses with concomitant administration of drugs, or because of side effects and/or due to extended dosing regimens, which may possibly lead to blindness.
  • the inventors of the present invention have appreciated the problems and shortfalls associated with the existing anti-glaucoma treatments and sought ways to address them.
  • An object of the present invention is to provide at least two anti-glaucoma agents in a form that provides improved patient compliance by decreasing the necessary frequency of administration and cost of the medication.
  • Another object of the present invention is to provide at least two anti -glaucoma agents in a form having improved surface area and solubility, and also reduced dose.
  • Yet another object of the present invention is to provide a fixed dose pharmaceutical composition comprising at least two anti-glaucoma agents having a reduced dose.
  • a fixed dose pharmaceutical composition comprising at least two anti-glaucoma agents and one or more pharmaceutically acceptable excipients.
  • the anti-glaucoma agents comprise a carbonic anhydrase inhibitor.
  • the anti-glaucoma agents comprise a prostaglandin derivative. More preferably, the anti-glaucoma agents present in the composition comprise a carbonic anhydrase inhibitor and a prostaglandin derivative.
  • the prostaglandin derivative is tafluprost.
  • the carbonic anhydrase inhibitor is dorzolamide, brinzolamide, acetazolamide or methazolamide.
  • the at least two anti- glaucoma agents comprise tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide or tafluprost and methazolamide.
  • a process for the preparation of a fixed dose pharmaceutical composition of the invention comprising mixing at least two anti-glaucoma agents with at least one or more pharmaceutically acceptable excipients; to provide the pharmaceutical composition.
  • a method of treating glaucoma and/or reducing intra ocular pressure comprising administering a fixed dose pharmaceutical composition according to the invention to a patient in need thereof.
  • a fixed dose composition of the invention for use in medicine comprises treatment of glaucoma and/or in reducing of intra ocular pressure.
  • a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of glaucoma and/or the reduction of intra ocular pressure.
  • the appropriate therapeutic modality must be selected based on the individual patient and the disease stage and type. Concomitant use of multiple drugs may increase adverse effects and reduce compliance. Generally speaking, when three or more drugs are required to control IOP, other therapeutic options such as laser treatment or invasive surgery should be considered.
  • Glaucoma is a chronic, progressive disease, requiring long-term administration of eye drops and periodic follow up of the patient, and as there are no symptoms in many cases, it is essential to secure the patient's cooperation in order to achieve therapeutic success.
  • Compliance in glaucoma drug treatment has been reported to be far worse than physicians believe. Non-compliance is an important factor in the progression of glaucomatous visual field damage. Therefore, compliance issues must be taken into account when the type of treatment is selected, and when visual field deterioration is observed, compliance issues must be verified before changing medications.
  • the improvement of compliance depends upon explanations of the disease, treatment, and adverse effects, keeping the treatment to a minimum, tailoring the treatment to the patient's lifestyle and providing proper administration guidance.
  • Such combination therapy may involve different dosage regimens as well as different frequencies of administration of anti-glaucoma agents and thus it generally may result in non- completion of therapy leading to the worsening of underlying disease as a result of such noncompliance, which is especially observed in patients.
  • the present invention provides a fixed dose pharmaceutical composition comprising anti glaucoma agents which would ensure patient compliance due to simplification of therapy.
  • the term "fixed dose composition” refers to a formulation comprising two or more active pharmaceutical ingredients combined in a single dosage form, wherein the composition comprises a combination of drugs present in a predetermined ratio.
  • Anti-glaucoma agents for use in the present invention include, but are not limited to the combinations of tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide, tafluprost and methazolamide.
  • the present invention thus provides a fixed dose pharmaceutical composition
  • a fixed dose pharmaceutical composition comprising a combination of tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide, as well as tafluprost and methazolamide.
  • Tafluprost is used in broad sense to include not only “Tafluprost” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • Dorzolamide is used in broad sense to include not only “Dorzolamide” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • the dorzolamide can be present in compositions of the invention in the form of a free base or a salt. An example of such a salt for use in the invention is dorzolamide hydrochloride.
  • Brinzolamide is used in broad sense to include not only “Brinzolamide” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • the brinzolamide can be present in compositions of the invention in the form of a free base or a salt.
  • Alcohol is used in broad sense to include not only “Acetazolamide” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • Metalzolamide is used in broad sense to include not only “Methazolamide” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • composition includes ocular dosage forms (solutions, suspensions, sol to gel systems, sprays, drops, liquid dispersions, suspensions, solutions, emulsions, gels, ointments, lotions, creams, ocular inserts, contact lenses, corneal shield, artificial tear inserts, subconjunctival inserts, filter paper strips, punctal plugs, liposomal preparations, injections, implants, depots) tablets, capsules (filled with powders, powders for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, multi unit pellet systems (MUPS), disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates), sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, multi unit pellet systems (MUPS), disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates) and sprinkles and
  • the fixed dose pharmaceutical composition are presented in an ocular dosage forms such as but not limited to solutions, suspensions, sol to gel systems, liposomal preparations, hydrogels, sprays, drops, liquid dispersions, suspensions, nanosuspensions, emulsions, microemulsions, gels, in situ gels, ointments, creams, ocular inserts, contact lenses, corneal shield, artificial tear inserts, subconjuctival inserts, colloidal drug delivery systems, nanoparticulates, microparticulates, niosomes, dendrimers, cyclodextrins, hydrogel systems, injections, implants, depots, punctual plugs, filter paper strips and the like.
  • an ocular dosage forms such as but not limited to solutions, suspensions, sol to gel systems, liposomal preparations, hydrogels, sprays, drops, liquid dispersions, suspensions, nanosuspensions, emulsions, microemulsions, gels, in situ gels, oin
  • the fixed dose pharmaceutical composition comprises tafluprost in an amount of from about 0.00005 to about 0.05% w/v.
  • the fixed dose pharmaceutical composition comprises dorzolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition comprising brinzolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition comprises acetazolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition comprises methazolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition comprises tafluprost in an amount of from about 0.00005 to about 0.05% w/v and dorzolamide in an amount of from about 0.1 to about
  • the fixed dose pharmaceutical composition comprises tafluprost in an amount of from about 0.00005 to about 0.05% w/v and brinzolamide in an amount of from about 0.1 to about
  • the fixed dose pharmaceutical composition comprises tafluprost in an amount of from about 0.00005 to 0.05% w/v and acetazolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition comprises tafluprost in an amount of from about 0.00005 to 0.05% w/v and methazolamide in an amount of from about 0.1 to about 15% w/v.
  • the fixed dose pharmaceutical composition may be administered once daily, twice daily or thrice daily.
  • the inventors of the present invention have further observed that the solubility properties of anti- glaucoma agents were improved by nanosizing leading to better bioavailability of the drug.
  • Nanonization of hydrophobic or poorly water-soluble drugs generally involves the production of drug nanocrystals through either chemical precipitation (bottom-up technology) or disintegration (top-down technology). Different methods may be utilized to reduce the particle size of the hydrophobic or poorly water soluble drugs. [Huabing Chen et ah, discusses the various methods to develop nanoformulations in "Nanonization strategies for poorly water-soluble drugs," Drug Discovery Today, Volume 00, Number 00, March 2010].
  • the present invention thus provides a fixed dose pharmaceutical composition
  • a fixed dose pharmaceutical composition comprising tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide, tafluprost and methazolamide wherein tafluprost, dorzolamide, brinzolamide acetazolamide and methazolamide are in the nanosize range.
  • nanosize refers to tafluprost, dorzolamide, brinzolamide acetazolamide and methazolamide particles having an average particle size of less than or equal to about 3000 nm.
  • particles refers to particles of tafluprost or dorzolamide, tafluprost or brinzolamide, tafluprost or acetazolamide, tafluprost or methazolamide.
  • the nanoparticles of the present invention can be obtained by any of the process such as but not limited to milling, precipitation, homogenization, high pressure homogenization, spray-freeze drying, supercritical fluid technology, emulsion/solvent evaporation, PRINT, thermal condensation, ultrasonication and spray drying.
  • the inventors of the present invention have also observed that the solubility properties of anti- glaucoma agents were improved by forming complexes with suitable complexing agents.
  • Cyclodextrins are one such water-soluble complexing agents that are able to solubilize poorly soluble lipophilic drugs, and enhance their permeation through biological membranes, through formation of water-soluble complexes.
  • the fixed dose compositions of the present invention may comprise one or more cyclodextrins.
  • excipients may be used for formulating the various dosage forms according to the present invention.
  • the composition of the invention may include excipients such as, but not limited to, vehicle, surfactant, antioxidants, polymers, stability enhancing agents, solubilizers, viscosity enhancing agents or suspending agents, lipids, isotonic agents, pH adjusting agent, preservatives, chelating agents, mucoadhesive agents, polyethoxylated castor oils and/or any combination thereof.
  • Surfactants are added in order to prevent the concentration of the prostaglandin derivatives from being lowered by improving water-solubility of the prostaglandin derivatives in the ophthalmic solution and by inhibiting the adsorption to the resinous container.
  • Suitable amphoteric, non- ionic, cationic or anionic surfactants may be included in the fixed dose pharmaceutical composition of the present invention.
  • Surfactants for use in the present invention may comprise of one or more, but not limited to Polysorbates such as polyoxyethylene fatty esters such as polysorbate 80 [poly(oxyethylene)sorbitan monooleate], polysorbate 60 [poly(oxyethylene)sorbitan monostearate], polysorbate 40 [poly(oxyethylene)sorbitan monopalmitate], poly(oxyethylene)sorbitan monolaurate, poly(oxyethylene)sorbitan trioleate and polysorbate 65 [poly(oxyethylene)sorbitan tristearate], polyoxyethylene hydrogenated castor oils such as Cremophor RH 40 (PEG-40 Hydrogenated Castor Oil), Cremophor EL, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50 and polyoxyethylene hydrogenated castor oil 60, polyoxyethylene polyoxypropylene glycols such as polyoxyethylene (160) polyoxypropylene (30) glycol [Pluronic F68], polyoxyethylene (42) polyoxypropylene
  • Carboxylates Sulphonates, Petroleum sulphonates, alkylbenzenesulphonates, Naphthalenesulphonates, Olefin sulphonates, Alkyl sulphates, Sulphates, Sulphated natural oils and fats, Sulphated esters, Sulphated alkanolamides, Alkylphenols, ethoxylated and sulphated, Ethoxylated aliphatic alcohol, polyoxy ethylene surfactants, carboxylic esters Polyethylene glycol esters, tocopherol polyethylene glycol succinate (TPGS), Anhydrosorbitol ester and it's ethoxylated derivatives, Glycol esters of fatty acids, Carboxylic amides, Monoalkanolamine condensates, Polyoxyethylene fatty acid amides, Quaternary ammonium salts, Amines with amide linkages, Polyoxyethylene alkyl and alicyclic amines, ⁇ , ⁇ , ⁇ , ⁇ tetraki
  • the surfactant is present in an amount from about 0.5% w/v or less.
  • Antioxidants are added in order to prevent the concentration of the prostaglandin derivatives from being lowered by inhibiting decomposition of the prostaglandin derivatives in the ophthalmic solution.
  • Specific examples of antioxidants such as, but not limited to, sodium nitrite, ascorbic acid, L-ascorbic acid stearate, sodium hydrogensulfite, alphathioglycerin, ethylenediaminetetraacetic acid, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol acetate, potassium dichloroisocyanurate, dibutylhydroxytoluene, 2,6-di-t-butyl-4-methylphenol, soybean lecithin, sodium thioglycollate, sodium thiomalate, natural vitamin E esters of vitamin E, tocopherol, ascorbyl pasthyminate, sodium pyrosulfite, butylhydroxyanisole, 1,3-butylene glycol, pentaerythtyl
  • the antioxidant is present in an amount from about 0.00005% w/v to about 0.5% w/v.
  • Viscosity enhancing agents and/or suspending agents may be employed to thicken the tear film and increase corneal contact time, i.e., reduce the rate of tear fluid drainage.
  • Such agents may include, but are not limited to, cellulose derivatives, methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone and polyvinyl alcohol, Carbomer 974 P , carboxy methyl cellulose, polyvinyl pyrrolidine, polyvinyl alcohol (PVA), carbopol, carbophil, cross-linked carboxyl-containing polymers, ethyl cellulose, acacia, agar, alginic acid, sodium alginate, bentonite, carrageenan, gelatin, tragacanth, xanthan gum, gellan gum, pectin, poloxamer, xyloglucan, Smart HydrogelTM, polymethacrylic acid - polyethylene glycol and combinations thereof.
  • PVA polyvinyl alcohol
  • the viscosity-enhancing and/or suspending agents are present in an amount from about 0.005% w/v to about 2 % w/v.
  • Mucoadhesive agents may also be incorporated in the fixed dose pharmaceutical compositions of the present invention, which may include, but are not limited to, Poly (acrylic acid), carbomer, hyaluronan, chitosan, sodium carboxymethylcellulose, poly(galactouronic acid), sodium alginate, pectin, xanthan gum, xyloglucan gum, scleroglucan, hydroxypropylmethylcellulose, methylcellulose, poly(vinyl alcohol), poly(vinyl pyrrolidone) and combinations thereof.
  • Poly acrylic acid
  • carbomer hyaluronan
  • chitosan sodium carboxymethylcellulose
  • sodium alginate pectin
  • xanthan gum xyloglucan gum
  • scleroglucan hydroxypropylmethylcellulose
  • methylcellulose poly(vinyl alcohol), poly(vinyl pyrrolidone) and combinations thereof.
  • Prostaglandin esters such as tafluprost are difficult to formulate in storage-stable solutions as they tend to be hydrolytically unstable.
  • the fixed dose pharmaceutical compositions of the present invention are storage stable. These compositions contain a stability-enhancing amount of a polyethoxylated castor oil, phosphonates, disodium edetate; sodium thiosulfate; and sodium stannate.
  • the polyethoxylated castor oils comprise, but are not limited to, PEG-2 to PEG-200 castor oils, as well as PEG-5 to PEG-200 hydrogenated castor oils or combinations thereof.
  • the one or more polyethoxylated castor oils are present in an amount from about 0.02 and to about 20.0 % w/v.
  • Suitable lipids which may be used for liposomal preparations may comprise or constitute phospholipids or phopholipid derivatives or natural phospholipids and the like.
  • the lipids may comprise a group selected from lecithins, pegylated lipids, phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidic acid (PA), DPG (bisphosphatidyl glycerol), PEOH (phosphatidyl alcohol) and cholesterol.
  • Phospholipids for pH sensitive liposomes such as DSPE- PG8MG/ DSPE-PG8CH and the like.
  • Suitable solubilizers may also be incorporated in the fixed dose pharmaceutical compositions of the present invention, which may include, but are not limited to, polysorbate 80, poly oxy ethylene hydrogenated castor oil 60, macrogol 4000, tyloxapol, fatty acid glycerol polyethylene glycol esters, fatty acid polyethylene glycol esters, polyethylene glycols, glycerol ethers, Cremophor EL or Cremophor RH 40* and the like or combinations thereof.
  • tonicity adjusting agents or isotonic agents include, but are not limited to, sodium chloride, potassium chloride, dextrose, mannitol, calcium chloride, glycerine/glycerol or propylene glycol and the like and combinations thereof; buffering agents or pH adjusting agent include, but are not limited to, acetic acid or salts thereof, boric acid or salts thereof, phosphoric acid or salts thereof; citric acid or salts thereof, tartaric acid or salts thereof, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium dihydrogen phosphate dihydrate, sodium carbonate, sodium hydrogen carbonate, trometamol, disodium hydrogen phosphate or epsilon -aminocaproic acid, tromethamine and the like and combinations thereof; preservatives include, but are not limited to, soft preservatives, benzalkonium chloride, benzylammonium chloride, cetylmethyl ammonium bromide
  • the fixed dose pharmaceutical compositions of the present invention may be preservative free.
  • the fixed dose pharmaceutical compositions of the present invention may be heat stable.
  • the storage temperature for an ophthalmic formulation may sometimes increase during distribution or storage.
  • a rise of the storage temperature causes a decrease in the desired drug efficacy or discoloration and formation of suspended matter.
  • the inventors of the present invention in order to prevent the degradation of a thermally unstable drug, have formulated heat stable fixed dose pharmaceutical compositions.
  • the fixed dose pharmaceutical compositions of the present invention have a pH of about 3 to 8, preferably from about 4 to 7 and an osmolality between 260 to 320 milliOsmoles per kilogram (mOsm/kg).
  • the fixed dose pharmaceutical compositions may further comprise sterile water for injection as a vehicle.
  • Other aqueous and non-aqueous vehicles may also be used as a vehicle.
  • the fixed dose pharmaceutical compositions of the present invention can be packed in a resinous container of material such as, but not limited to, polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, acrylic resins, polystyrene, polymethyl methacrylate and nylon. These resins can be high-density resins or low-density resins.
  • the fixed dose pharmaceutical compositions are packaged in a "small volume” container.
  • the term "small volume” container shall mean a container of a size sufficient to hold a quantity of the fixed dose pharmaceutical composition sufficient for 1 - 3 doses per day over 1 - 2 months, generally about 20 mL or less.
  • small volume containers include 5 mL, 10 mL and 15 mL sized bottles.
  • Small volume bottles made from syndiotactic polypropylene are easier to squeeze than those made from isotactic polypropylene, and oval bottles are easier to squeeze than round bottles.
  • the aqueous compositions adapted for topical ophthalmic administration are preferably packaged in oval, syndiotactic polypropylene bottles.
  • the fixed dose pharmaceutical compositions of the present invention may be dispensed in a unit dose container or a multi dose container.
  • compositions may also be administered in the form of punctual plugs made of silicone, collagen and the like, implants, inserts would also be preferred as per need.
  • a process for preparing the fixed dose pharmaceutical composition of the present invention comprises (a) adding the active agents to the vehicle and optionally other excipients (b) making up the volume with vehicle followed by aseptic filtration.
  • the present invention also provides a method of reducing intra ocular pressure by administering a fixed dose pharmaceutical composition comprising tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide, tafluprost and methazolamide.
  • the present invention also provides the use of treating glaucoma by administering a fixed dose pharmaceutical composition comprising tafluprost and dorzolamide, tafluprost and brinzolamide, tafluprost and acetazolamide, tafluprost and methazolamide.
  • the fixed dose pharmaceutical composition of the present invention may further comprise at least one additional preventive or therapeutic drug for glaucoma or ocular hypertension, wherein the other preventive or therapeutic classes of drugs for glaucoma or ocular hypertension is selected from, but are not limited to, nonselective sympathomimetic drug, an a2-receptor agonist, an a 1 -receptor antagonist, a ⁇ -receptor antagonist, a parasympathomimetic drug and a Rho-kinase inhibitor.
  • the nonselective sympathomimetic drugs include dipivefrin, a2- receptor agonist agents includes brimonidine or apraclonidine, al -receptor antagonist agent includes bunazosin, ⁇ -receptor antagonist includes timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol, parasympathomimetic drug includes pilocarpine.
  • Example 1 is for the purpose of illustration of the invention only and is not intended in any way to limit the scope of the present invention.
  • Example 1 is for the purpose of illustration of the invention only and is not intended in any way to limit the scope of the present invention.
  • step (3) The solution obtained in step (1) was added to the solution obtained in step (2) and the final volume was made with water for injection and was aseptically filtered.
  • step (3) The solution obtained in step (1) was added to the solution obtained in step (2) and the final volume was made with water for injection and was aseptically filtered.
  • step (3) The solution obtained in step (1) was added to the solution obtained in step (2) and the final volume was made with water for injection and was aseptically filtered.
  • step (3) The solution obtained in step (1) was added to the solution obtained in step (2) and the final volume was made with water for injection and was aseptically filtered.
  • Tafluprost and Dorzolamide heat stable ophthalmic solution
  • step (3) The solution obtained in step (1) was added to the solution obtained in step (2) and the volume was made up with water for injection and was aseptically filtered.
  • step (3) The solution obtained in step (3) was added to step (2) and the pH was adjusted with NaOH/ HC1 and was bulk sterilized.
  • step (4) The solution obtained in step (4) was cooled and the tafluprost solution obtained in step (1) was added to it.
  • Brinzolamide was aseptically added to tyloxapol and fourth part quantity of water for injection and was homogenized to obtain a slurry.
  • step (6) The slurry obtained in step (6) was milled and subjected to microfilteration.
  • step (7) The milled slurry obtained in step (7) was added to the solution obtained in step (5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/GB2014/051772 2013-06-13 2014-06-10 Fixed Dose Pharmaceutical Composition WO2014199131A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2015/MUM/2013 2013-06-13
IN2015MU2013 IN2013MU02015A (enrdf_load_stackoverflow) 2013-06-13 2014-06-10

Publications (1)

Publication Number Publication Date
WO2014199131A1 true WO2014199131A1 (en) 2014-12-18

Family

ID=51022895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/051772 WO2014199131A1 (en) 2013-06-13 2014-06-10 Fixed Dose Pharmaceutical Composition

Country Status (2)

Country Link
IN (1) IN2013MU02015A (enrdf_load_stackoverflow)
WO (1) WO2014199131A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918891A1 (fr) * 2007-07-20 2009-01-23 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US20100093789A1 (en) * 2007-02-27 2010-04-15 Asahi Kasei Pharma Corporation Sulfonamide compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093789A1 (en) * 2007-02-27 2010-04-15 Asahi Kasei Pharma Corporation Sulfonamide compound
FR2918891A1 (fr) * 2007-07-20 2009-01-23 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Impact of prostaglandin-F (2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness - a cross-sectional study on 403 eyes", KLIN MONBL AUGENHEILKD, vol. 221, no. 9, September 2004 (2004-09-01), pages 753 - 6
HUABING CHEN ET AL.: "Nanonization strategies for poorly water-soluble drugs", DRUG DISCOVERY TODAY, vol. 00, no. 00, March 2010 (2010-03-01)
TAKAHIRO AKAISHI ET AL: "Ocular Hypotensive Effects of Anti-Glaucoma Agents in Mice", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 25, no. 5, 1 October 2009 (2009-10-01), pages 401 - 408, XP055134428, ISSN: 1080-7683, DOI: 10.1089/jop.2009.0006 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
IN2013MU02015A (enrdf_load_stackoverflow) 2015-07-10

Similar Documents

Publication Publication Date Title
JP7726542B2 (ja) ピリジルアミノ酢酸化合物を含む医薬製剤
JP6704400B2 (ja) 眼科用液剤
Andrés-Guerrero et al. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
US11331311B2 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
EP3706715A1 (en) Ophthalmic pharmaceutical composition containing a combination of brinzolamide and brimonidine and method of preparation thereof
WO2019131901A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬製剤
US12336971B2 (en) Ophthalmic pharmaceutical compositions and uses thereof
WO2014199131A1 (en) Fixed Dose Pharmaceutical Composition
JP2022001606A (ja) エピナスチン又はその塩を含有する水性組成物
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
GR1009616B (el) Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
HK40005358A (en) Eye-drop composition for lowering intraocular pressure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14733680

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14733680

Country of ref document: EP

Kind code of ref document: A1